ArticleAntimicrobial agents and chemotherapy1999
In vitro anti-Helicobacter pylori activities of new rifamycin derivatives, KRM-1648 and KRM-1657.
Article in Antimicrobial agents and chemotherapy, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 59 citations in OpenAlex.
- Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate helicobacter pylori infection.BMC gastroenterology · 2007Trial
- CoccoidVirulence · 2025Review
- Antimicrobial combinations againstMicrobiology spectrum · 2024Article
- Exploring Alternative Treatment Choices for Multidrug-Resistant Clinical Strains ofMicroorganisms · 2023Article
- Therapeutic efficacy of rifalazil (KRM-1648) in a M. ulcerans-induced Buruli ulcer mouse model.PloS one · 2022Article
- Toxin-Antitoxin Systems - A New Player in Morphological Transformation of Antibiotic-ExposedFrontiers in cellular and infection microbiology · 2021Article
- Rifabutin for the Treatment ofPathogens (Basel, Switzerland) · 2020Review
- BestAntibiotics (Basel, Switzerland) · 2020Review
- Alternative eradication regimens forInfection and drug resistance · 2019Article
- Rifabutin and Furazolidone Could Be the Candidates of the Rescue Regimen for Antibiotic-ResistantThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2019Article
- Effective therapeutic regimens in two South Asian countries with high resistance to majorAntimicrobial resistance and infection control · 2019Article
- Rescue Therapy with a Proton Pump Inhibitor Plus Amoxicillin and Rifabutin for Helicobacter pylori Infection: A Systematic Review and Meta-Analysis.Gastroenterology research and practice · 2015Review
- Recent Insights into Antibiotic Resistance in Helicobacter pylori Eradication.Gastroenterology research and practice · 2012Article
- Rescue therapy using a rifabutin-based regimen is effective for cure of Helicobacter pylori infection.Canadian journal of gastroenterology = Journal canadien de gastroenterologie · 2010Article
- Second-line rescue therapy of helicobacter pylori infection.Therapeutic advances in gastroenterology · 2009Article
- "Rescue" regimens after Helicobacter pylori treatment failure.World journal of gastroenterology · 2008Review
- Who's Winning the War? Molecular Mechanisms of Antibiotic Resistance in Helicobacter pylori.Current drug therapy · 2008Article
- Quantifying gastric Helicobacter pylori infection: a comparison of quantitative culture, urease breath testing, and histology.Digestive diseases and sciences · 2007Article
- Efficacy of novel rifamycin derivatives against rifamycin-sensitive and -resistant Staphylococcus aureus isolates in murine models of infection.Antimicrobial agents and chemotherapy · 2006Article
- Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters.Antimicrobial agents and chemotherapy · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The new rifamycin derivatives KRM-1657 and KRM-1648 were evaluated for their in vitro antimicrobial activities against 44 strains of Helicobacter pylori. Although the drugs were not very active against other gram-negative bacteria, the MICs at which 90% of isolates are inhibited for these drugs were lower (0.002 and 0.008 microgram/ml, respectively) than those of amoxicillin and rifampin for H. pylori. Time-kill studies revealed that the bactericidal activities of these agents were due to cell lysis. The results presented here indicate that these new rifamycin derivatives may be useful for the eradication of H. pylori infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.